江中药业：股权激励上调业绩考核目标内外部资源整合有望加速

长城证券股份有...01-03 19:12

事件：1 月1 日，公司发布第二期限制性股票激励计划（草案修订版），拟向激励对象授予不超过687.70 万股，占公司股本总额的1.09%，激励对象不超过170 人，授予价格为13.70 元/股。股权激励上调业绩考核目标。根据草案修订版最低要求，2025-2027 年归母净利润分别为8.88/9.95/11.14 亿元，较第一版草案，2025-2026 年归母净利润目标分别提升了1.16/1.53 ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2500219107?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-01-03 19:12","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2500219107","market":"hk","top_or_hot":-1,"title":"江中药业：股权激励上调业绩考核目标 内外部资源整合有望加速","media":"长城证券股份有...","content":"<div>\n<p>事件：1 月1 日，公司发布第二期限制性股票激励计划（草案修订版），拟向激励对象授予不超过687.70 万股，占公司股本总额的1.09%，激励对象不超过170 人，授予价格为13.70 元/股。股权激励上调业绩考核目标。根据草案修订版最低要求，2025-2027 年归母净利润分别为8.88/9.95/11.14 亿元，较第一版草案，2025-2026 年归母净利润目标分别提升了1.16/1.53 ...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025010319120895f7adc4&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>江中药业：股权激励上调业绩考核目标 内外部资源整合有望加速</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n江中药业：股权激励上调业绩考核目标 内外部资源整合有望加速\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-01-03 19:12 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025010319120895f7adc4&s=b><strong>长城证券股份有...</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>事件：1 月1 日，公司发布第二期限制性股票激励计划（草案修订版），拟向激励对象授予不超过687.70 万股，占公司股本总额的1.09%，激励对象不超过170 人，授予价格为13.70 元/股。股权激励上调业绩考核目标。根据草案修订版最低要求，2025-2027 年归母净利润分别为8.88/9.95/11.14 亿元，较第一版草案，2025-2026 年归母净利润目标分别提升了1.16/1.53 ...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025010319120895f7adc4&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2088748020.USD","symbol_name":"EASTSPRING INVESTMENTS ASIA REAL ESTATE MULTI ASSE \"ADM\" (USD) INC A","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025010319120895f7adc4&s=b","article_id":"2500219107","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025010319120895f7adc4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2500219107","pubTimestamp":1735902722,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"总体来看，公司股权激励目标的提高体现了国资委对公司未来发展寄予更高期望，我们预计公司会加大内外部资源的整合和利用，提升资本利用率。江中药业作为华润集团一级利润中心，新增产业链相关任务，有望助力华润集团链长建设。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU2088748020.USD":"EASTSPRING INVESTMENTS ASIA REAL ESTATE MULTI ASSE \"ADM\" (USD) INC A","BK1570":"华润系","BK1240":"房地产开发","SG9999010052.SGD":"United Asia Pacific Real Estate Income Dis SGD","LU0414403682.SGD":"Blackrock Asia Pacific Equity Income A5 SGD-H","LU0067412154.USD":"UBS (LUX) EQUITY FUND -  CHINA OPPORTUNITY \"P\" (USD) ACC","LU0348825331.USD":"ALLIANZ CHINA EQUITY \"A\" (USD) INC","BK1555":"内房股","BK1521":"挪威政府全球养老基金持仓","LU1152091754.HKD":"UBS (LUX) EQUITY FUND - CHINA OPPORTUNITY (USD) \"PM\" (HKD) INC","LU0738912210.USD":"Blackrock Asia Pacific Equity Income A6 USD","LU0370786039.SGD":"Fidelity Greater China A-SGD","LU0287142896.SGD":"Fidelity China Focus A-SGD","LU1008478684.HKD":"UBS (LUX) EQUITY FUND -  CHINA OPPORTUNITY \"P\" (HKD) ACC","LU0594300419.USD":"富达中国消费基金A","LU1152091168.USD":"UBS (LUX) EQUITY FUND - CHINA OPPORTUNITY (USD) \"PM\" INC","LU2088748376.SGD":"Eastspring Investments - Asia Real Estate Multi Asset Income Cl ASDM SGD-H","LU0594300179.USD":"FIDELITY CHINA CONSUMER \"A\" (USD) ACC","SG9999009997.SGD":"United Asia Pacific Real Estate Income Acc SGD","LU1960683339.HKD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (HKD) ACC","LU0417516902.SGD":"Allianz China Equity Cl AT Acc SGD","LU0251144936.SGD":"Fidelity Sustainable Asia Equity A-SGD","LU2088747998.USD":"EASTSPRING INVESTMENTS ASIA REAL ESTATE MULTI ASSE \"ADM\" (USD) INC","LU0173614495.USD":"富达中国焦点A","LU0359201612.USD":"贝莱德中国基金A2","LU1880383366.USD":"东方汇理中国股票基金 A2 (C)","LU0359202008.SGD":"Blackrock China Fund A2 SGD-H","LU1023057109.AUD":"BGF CHINA \"A2\" (AUDHDG) ACC","LU0650527681.SGD":"Fidelity China Consumer A-SGD","LU1993786604.SGD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (SGD) ACC","LU1807302812.USD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (USD) ACC","LU1366334578.USD":"ALLSPRING EMERGING MARKETS EQUITY INCOME \"A\" (USD) INC","LU2088747725.USD":"EASTSPRING INVESTMENTS ASIA REAL ESTATE MULTI ASSE \"A\" (USD) ACC","SG9999010078.USD":"UNITED ASIA PACIFIC REAL ESTATE INCOME (USDHDG) INC","BK1589":"北水核心资产","LU0072913022.USD":"UBS (LUX) EQUITY FUND -  GREATER CHINA \"P\" (USD) ACC","LU0880133367.SGD":"UBS (LUX) EQUITY FUND CHINA OPPORTUNITY USD \"P\" (SGD) ACC","LU0048580855.USD":"富达大中华区A","LU0791590937.USD":"ALLSPRING  EMERGING MARKTES EQUITY INCOME \"A\" (USD)","LU0501845795.SGD":"瑞银大中华区股票基金P Acc SGD","LU0791591158.USD":"ALLSPRING  EMERGING MARKTES EQUITY INCOME \"I\" (USD) ACC","LU0605514214.HKD":"FIDELITY CHINA CONSUMER \"A\" (HKD) ACC","01109":"华润置地","LU2088748293.HKD":"EASTSPRING INVESTMENTS ASIA REAL ESTATE MULTI ASSE \"AHD\" (HKD) INC","LU1366334651.USD":"ALLSPRING EMERGING MARKETS EQUITY INCOME \"I\" (USD) INC","SG9999014674.SGD":"Nikko AM All China Equity A SGD","IE0008368742.USD":"首域中国增长基金I Acc","LU0048597586.USD":"富达亚洲焦点A"},"translate_title":"Jiangzhong Pharmaceutical: Equity incentives raise performance appraisal targets, integration of internal and external resources is expected to accelerate","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01109":0.9},"content_text":"事件：1 月1 日，公司发布第二期限制性股票激励计划（草案修订版），拟向激励对象授予不超过687.70 万股，占公司股本总额的1.09%，激励对象不超过170 人，授予价格为13.70 元/股。股权激励上调业绩考核目标。根据草案修订版最低要求，2025-2027 年归母净利润分别为8.88/9.95/11.14 亿元，较第一版草案，2025-2026 年归母净利润目标分别提升了1.16/1.53 亿元。2024 年前三季度公司实现营收29.72亿元（yoy-8.19%），实现归母净利润6.34 亿元（yoy+7.09%），收入端承压利润端增速放缓，主要受2023 年高基数、处方药部分产品未中标、整体消费不景气大健康拓展不及预期等因素影响。此外，草案修订版对投入资本回报率指标的要求为每年不低于15.42%，较第一版草案上调了1.82pct，2023/2024 前三季度投入资本回报率分别为15.91%/14.55%。总体来看，公司股权激励目标的提高体现了国资委对公司未来发展寄予更高期望，我们预计公司会加大内外部资源的整合和利用，提升资本利用率。新增产业链相关任务，助力华润集团链长建设。近年来，国务院国资委不断发力，推动中央企业打造现代产业链“链长”，提升重点产业链的韧性和安全水平，截至2022 年底，国务院国资委先后分两批遴选出16 家“链长”企业，主动在重要行业、关键领域进行布局。根据《国资报告》，华润集团针对制约中药产业发展的痛点10 项、急需补短板的方面18 项、锻长板的节点17 项，提出了10 项重大工程、33 项重点任务、93 条具体举措。江中药业作为华润集团一级利润中心，新增产业链相关任务，有望助力华润集团链长建设。投资建议：江中药业是高分红+优质品牌OTC 企业，聚焦胃肠领域，补充完善咽喉咳喘、补益、康复、营养等品类，通过“内生+外延”双轮驱动，积极探索线上渠道。我们看好公司未来通过品类扩张和渠道加强带来的营收增长和华润管理体系下的协同优化。预计公司2024-2026 年实现营收42.75/47.56/54.25 亿元，分别同比增长-3%/11%/14%；实现归母净利润7.95/9.02/10.38 亿元，分别同比增长12%/13%/15%；对应PE 估值分别为18/16/14X，维持“增持”评级。风险提示：宏观经济波动风险；政策风险；行业竞争加剧；成本波动风险；产品推广不及预期；研发风险。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.4","shortVersion":"4.29.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2500219107"}

江中药业：股权激励上调业绩考核目标 内外部资源整合有望加速

精彩评论

江中药业：股权激励上调业绩考核目标内外部资源整合有望加速